Tenderwize
Back to tender search

Non-exclusive pharmaceutical discount agreement for Glyceroltrinitrat (ATC: C05AE01)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Oct 31, 2026 · 22 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Glyceroltrinitrat (ATC-Code nach WHO: C05AE01)

50/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

50 / 100

Complexity

40 / 100

Risk factors

Purchase volume is unpredictable, dependent on prescription behavior and patient numbers; no minimum quantity guarantee...

Buyer may terminate the Open House and existing agreements if exclusive discount agreements are signed (typically 8-12...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Oct 31, 2026

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Conclusion of non-exclusive discount agreements for pharmaceutical products with active ingredient Glyceroltrinitrat (ATC: C05AE01)
  • Open House model: any eligible pharmaceutical entrepreneur can participate
Show full summary

Non-exclusive pharmaceutical discount agreements (Rabattvereinbarungen) under §130a(8) SGB V for the active ingredient Glyceroltrinitrat (ATC: C05AE01) via an Open House model. Buyer is AOK PLUS for the regions of Saxony and Thuringia, Germany. The process is open to all eligible pharmaceutical entrepreneurs; no competitive award, all qualified participants are accepted. Contract ends 31 October 2026. Purchase volume and value are unknown. The notice clarifies this is not a public procurement subject to EU procurement law.

Risks

Purchase volume is unpredictable, dependent on prescription behavior and patient numbers; no minimum quantity guarantee...

Buyer may terminate the Open House and existing agreements if exclusive discount agreements are signed (typically 8-12...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG
  • No connections to Russia per EU sanctions (Regulation 833/2014)

Administrative

  • Complete and submit documents via DTVP portal

Requirements may be incomplete.

Award Criteria

Lot 1

No specific award criteria disclosed; this is a non-competitive Open House model.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive pharmaceutical discount agreement for Glyceroltrinitrat (ATC: C05AE01)

Conclusion of non-exclusive discount agreements for pharmaceutical products with active ingredient Glyceroltrinitrat. Open House model: all interested pharmaceutical companies meeting conditions can participate; no individual negotiations; no exclusivity; no minimum purchase quantities; rolling submissions until final deadline.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Jun 2025 - Oct 2026

Category

Pharmaceutical products

Award Criteria

No specific award criteria disclosed; this is a non-competitive Open House model.

Deadline

Deadline Oct 31, 2026

Procurement Details

Publication date
29 May 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
346931-2025

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30